The decision comes after a state-of-emergency was declared in Washington, DC, due to the ongoing outbreak of COVID-19.
On March 16, 2020, Kevin Ott, director of the Bio-Process Systems Alliance (BPSA) announced in an email to BPSA members and contacts that the BPSA Summit scheduled for July 15–17, 2020 in Washington, DC, will be postponed for a later date in fall 2020. The decision comes after a state-of-emergency was declared in Washington, DC, due to the ongoing outbreak of COVID-19.
“The decision to postpone our 10th Anniversary BPSA Summit was not an easy one to make, but we believe this is the proper course of action given the uncontrollable externalities we all face at the moment,” Ott said in the email. “We believe this to be a prudent business decision, and it is unanimously supported by the BPSA [e]xecutive [c]ommittee.”
Source: BPSA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.